Immix Biopharma, Inc. (NASDAQ:IMMX) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analyst consensus: Six firms give Immix Biopharma a consensus rating of "Moderate Buy" (four buys, one hold, one sell) with an average 12‑month price target of $18.25 and individual targets as high as $23.
• Stock and financials: Shares opened at $9.53 (12‑month range $1.78–$11.61) with a market cap around $505M; the company reported a quarterly EPS of ($0.28) that missed estimates and analysts forecast about -0.79 EPS for the year.
• Business focus: Immix is a clinical‑stage immuno‑oncology company developing myeloid‑checkpoint therapies, led by IMX‑110, a first‑in‑class combination designed to activate macrophages and dendritic cells in the tumor microenvironment.

Shares of Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $18.25.

Several equities analysts recently weighed in on IMMX shares. Morgan Stanley started coverage on Immix Biopharma in a research note on Wednesday, March 25th. They issued an "overweight" rating and a $20.00 price target for the company. Mizuho boosted their price objective on Immix Biopharma from $14.00 to $15.00 and gave the stock an "outperform" rating in a research note on Monday, March 30th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immix Biopharma in a research note on Tuesday, April 21st. HC Wainwright boosted their price objective on Immix Biopharma from $12.00 to $15.00 and gave the stock a "buy" rating in a research note on Friday, March 27th. Finally, Citizens Jmp reiterated a "market outperform" rating and set a $23.00 price objective on shares of Immix Biopharma in a research note on Friday, March 27th.

Institutional Investors Weigh In On Immix Biopharma

A number of large investors have recently made changes to their positions in IMMX. Allworth Financial LP purchased a new stake in shares of Immix Biopharma in the fourth quarter valued at approximately $30,000. Mathes Company Inc. purchased a new stake in shares of Immix Biopharma in the fourth quarter valued at approximately $56,000. Balyasny Asset Management L.P. acquired a new position in Immix Biopharma in the fourth quarter valued at approximately $67,000. Kera Capital Partners Inc. acquired a new position in Immix Biopharma in the fourth quarter valued at approximately $68,000. Finally, Velan Capital Investment Management LP boosted its position in shares of Immix Biopharma by 40.0% during the third quarter. Velan Capital Investment Management LP now owns 35,000 shares of the company's stock worth $73,000 after buying an additional 10,000 shares during the period. 11.26% of the stock is currently owned by hedge funds and other institutional investors.

Immix Biopharma Stock Down 3.2%

Shares of Immix Biopharma stock opened at $9.53 on Tuesday. Immix Biopharma has a twelve month low of $1.78 and a twelve month high of $11.61. The business has a 50-day moving average price of $9.20 and a 200 day moving average price of $6.37. The firm has a market cap of $505.20 million, a PE ratio of -10.71 and a beta of 0.20.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.12). On average, sell-side analysts expect that Immix Biopharma will post -0.79 EPS for the current year.

Immix Biopharma Company Profile

Immix Biopharma NASDAQ: IMMX is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company's approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company's lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.